SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Recruiting now · Phase 2/Phase 3
Conditions studied: Non-Small Cell Lung Cancer
In brief
The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are: Will spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection rate of patients with initially unresectable stage Ⅲ non-small cell lung cancer? What adverse reactions will patients experience when receiving spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment?
Key facts
- Study ID
- NCT07131319
- Run by
- Second Affiliated Hospital of Nanchang University
- People needed
- 30
- Starts
- 2025-04-21
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2026-06-25
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- The patient has histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) that is deemed unresectable after discussion in the multidisciplinary team (MDT), which is classified as T3-4N1-2M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC).
You may not qualify if…
- Has participated in another clinical study using research products within the past 3 weeks.
Where it is running
- Nanchang City, Jiangxi Province — Nanchang, Jiangxi, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.